

NOVAVAX INC  
Form 8-K  
July 26, 2017

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): July 24, 2017**

**NOVAVAX, INC.**

**(Exact name of registrant as specified in charter)**

**Delaware**

**(State or Other Jurisdiction  
of Incorporation)**

**0-26770**

**(Commission File Number)**

**22-2816046**

**(I.R.S.  
Employer**

**Identification  
No.)**

**20 Firstfield Road**

**Gaithersburg, Maryland 20878**

**(Address of Principal Executive Offices, including Zip Code)**

**(240) 268-2000**

**(Registrant's telephone number, including area code)**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01. Other Events.**

*Topline RSV F Vaccine Data from Phase 2 Clinical Trial in Older Adults*

On July 24, 2017, Novavax, Inc. (the “Company”) issued a press release announcing topline data from the Company’s Phase 2 safety and immunogenicity trial of its RSV F Vaccine in older adults. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d)Exhibits

**Exhibit**

**Description**

**No.**

99.1	Press release, dated July 24, 2017, regarding the Company’s topline RSV F Vaccine data from its Phase 2 clinical trial in older adults.
------	---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Novavax, Inc.  
(Registrant)

Date:  
July  
26,  
2017

By: /s/ John A. Herrmann III

Name: John A. Herrmann III  
Senior Vice President, General Counsel and

Title:  
Corporate Secretary

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release, dated July 24, 2017, regarding the Company's topline RSV F Vaccine data from its Phase 2 clinical trial in older adults.